Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders

FDA nod to AstraZeneca’s Imfinzi plus FLOT chemotherapy for early and locally advanced gastric cancer

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies

Solventum to acquire Acera Surgical in $725 million deal

Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership

The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating

Gilead delivers groundbreaking HIV prevention drug to Eswatini & Zambia

The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval

Texas hits Sanofi, Bristol-Myers Squibb with lawsuit over blood thinner drug efficacy

Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan